ArticleThe New England journal of medicine2017
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
No numbers read from the abstract.
4 papers cite it
this papercites it
ArticleThe New England journal of medicine2017
No numbers read from the abstract.